Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Nov 13 - Nov 18
& Goldstein, J
The key findings from this clinical program include significant reductions in body weight and fat mass in treatment groups compared to placebo, preferential loss of abdominal and visceral adipose tissue, no changes in serum IGF-1 levels at any dose tested, no negative effects on glucose metabolism or insulin sensitivity, no significant adverse events related to metabolic or endocrine disruption, and safety profile indistinguishable from placebo for most parameters
Compounded tirzepatide from licensed 503B pharmacies may reduce cost by 6070% compared to brand-name Mounjaro or Zepbound, though purity verification becomes the users responsibility
Research-grade BPC-157 was commonly listed in 2026 from about $49 to $100 per vial, with 5 mg and 10 mg the usual sizes
